Trial Profile
Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Mar 2022
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Fulvestrant; Tamoxifen
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 03 Feb 2021 Primary outcome measure changed from efficacy endpoint to safety endpoint.
- 03 Feb 2021 Status changed from active, no longer recruiting to completed.
- 28 May 2019 Results presented in the Sysmex Corporation media release.